



## References – Clinical studies

### EQUIA® Forte

<b>TITLE</b>	<b>Comparative evaluation of postoperative sensitivity in bulk fill restoratives: A randomized controlled trial</b>
<b>REFERENCE</b>	Hirani RT <i>et al</i> , J Int Soc Prev Community Dent. 2018 Nov-Dec;8(6):534-539. doi: 10.4103/jispcd.JISPCD_218_18
Patients treated with EQUIA Forte and Activa Bioactive presented lower POS when compared to groups restored with Cention N.	
Number of Patients evaluated: 144 patients	

<b>TITLE</b>	<b>Glass hybrid restorations as an alternative for restoring hypomineralized molars in the ART model</b>
<b>REFERENCE</b>	Grossi J <i>et al</i> , BMC Oral Health (2018) 18:65 doi: 10.1186/s12903-018-0528-0
A success rate of 98.3% was observed after 6 and 12 months. The only failure occurred in a restoration involving three or more surfaces presenting the breakdown of all cusps.	
Number of Patients evaluated: 44 patients Number of restorations: 60 restorations	

<b>TITLE</b>	<b>Multi-center clinical evaluation of bulk-fill glass hybrid restorations: One-year report</b>
<b>REFERENCE</b>	Turkun S <i>et al</i> , J Dent Res Vol 97(Spec Iss B): 1972. <a href="https://iadr2018.zerista.com/event/member/492513">https://iadr2018.zerista.com/event/member/492513</a>
In this split-mouth study design, EQUIA Forte and the composite Tetric EvoCeram were equally successful in moderate to large size Class II restorations	
Number of Patients evaluated: 180 patients Number of restorations: 360 restorations	

<b>TITLE</b>	<b>12-month clinical-performance of a glass-hybrid-restorative in non-carries-cervical-lesions of patients with bruxism</b>
<b>REFERENCE</b>	Gurgan S <i>et al</i> , J Dent Res Vol 97(Spec Iss B):2448. <a href="https://iadr2018.zerista.com/event/member/492524">https://iadr2018.zerista.com/event/member/492524</a>
EQUIA Forte performed as successfully as the composite (Ceram. X Mono) in NCCLs of patients with bruxism.	
Number of Patients evaluated: 25 patients Number of restorations: 148 restorations	



## References – Clinical studies

### EQUIA® Forte

<b>TITLE</b>	<b>Does the depth of the cavity and the activity of the lesion in primary molars influence in the success of the restoration?</b>
<b>REFERENCE</b>	Baumotte L <i>et al</i> , J Dent Res Vol 98 (Spec Iss A): 0605 <a href="https://iadr2019.zerista.com/event/member/582088">https://iadr2019.zerista.com/event/member/582088</a>
EQUIA Forte showed a success rate of 94% after a mean evaluation time of 13.3 months. Cavity depth and caries lesion activity did not influence the restoration's survival.	
Number of Restorations: 45 restorations	

<b>TITLE</b>	<b>Two-year multicentre clinical evaluation of glass hybrid system vs. resin composite</b>
<b>REFERENCE</b>	Miletic I <i>et al</i> , J Dent Res Vol 98 (Spec Iss A): 3733 <a href="https://iadr2019.zerista.com/event/member/582960">https://iadr2019.zerista.com/event/member/582960</a>
EQUIA Forte presented a good clinical performance, similar to composite (Tetric EvoCeram) in a split mouth study design.	
Number of Patients evaluated: 180 patients Number of restorations: 360 restorations	

<b>TITLE</b>	<b>Glass Hybrid Versus Composite for Restoration of Non-cariou Cervical Lesions</b>
<b>REFERENCE</b>	Göstemeyer G <i>et al</i> , J Dent Res Vol 98 (Spec Iss A): 3725, <a href="https://iadr2019.zerista.com/event/member/582952">https://iadr2019.zerista.com/event/member/582952</a>
After 36 months, survival rate of EQUIA Forte was similar to that of nano-hybrid composite (Filtek Supreme XTE). EQUIA Forte restorations required less treatment time.	
Number of Patients evaluated: 88 patients Number of restorations: 175 restorations	

<b>TITLE</b>	<b>Twenty-four-month clinical performance of a glass hybrid restorative in non-cariou cervical lesions of patients with bruxism: a split-mouth, randomized clinical trial</b>
<b>REFERENCE</b>	Koc Vural U <i>et al</i> , Clin Oral Investig. 2020 Mar;24(3):1229-1238. doi: 10.1007/s00784-019-02986-x
EQUIA Forte showed good performance for the restoration of NCCLs when compared to Ceram.X One Universal. Cumulative survival rates was 84.1%	
Number of Patients evaluated: 25 patients Number of restorations: 148 restorations	



## References – Clinical studies

### EQUIA® Forte

<b>TITLE</b>	High-viscosity glass ionomer used with selective cavity preparation in MIH
<b>REFERENCE</b>	Sezer B <i>et al</i> , J Dent Res Vol 98 (Spec Iss B): 0568 <a href="https://www.ced-iadr2019.com/Madrid_Abstract_BOOK_Sept_7.pdf">https://www.ced-iadr2019.com/Madrid_Abstract_BOOK_Sept_7.pdf</a>
<b>After 2 years, EQUIA Forte presented a high survival rate in MIH affected first permanent molars. The probability of being satisfied at 12 months and 24 months were respectively 88,2%,78.6%.</b>	
<b>Number of Patients evaluated: 58 patients Number of restorations: 134 restorations</b>	

<b>TITLE</b>	Clinical performance of a glass hybrid restorative in extended size class II cavities
<b>REFERENCE</b>	Gurgan S <i>et al</i> , Oper. Dent. 2019 Oct 29. doi: 10.2341/18-282-C
<b>EQUIA Forte performed as good as the micro-hybrid composite (G-ænial Posterior), with a success rate of 100% at the 24-month recall.</b>	
<b>Number of Patients evaluated:37 patients Number of restorations: 108 restorations</b>	

<b>TITLE</b>	48-Month clinical performance of a glass hybrid in extended size class II cavities
<b>REFERENCE</b>	Gurgan S. <i>et al</i> , J Dent Res Vol 99 (Spec Iss A): 1389 <a href="https://iadr2020.zerista.com/event/member/678011">https://iadr2020.zerista.com/event/member/678011</a>
<b>EQUIA Forte and the micro-hybrid composite (G-ænial Posterior) presented acceptable surface and marginal adaptation characteristics, rendering the glass hybrid a trustable permanent material for large Class II cavities.</b>	
<b>Number of Patients evaluated: 32 patients Number of restorations: 90 restorations</b>	

<b>TITLE</b>	ART restorations in MIH severely affected molars: 4 years follow-up
<b>REFERENCE</b>	Marques M. <i>et al</i> , J Dent Res Vol 99 (Spec Iss A): 2384 <a href="https://iadr2020.zerista.com/event/member/677327">https://iadr2020.zerista.com/event/member/677327</a>
<b>The survival rate was 61.9% after a 48 months. EQUIA Forte is a trustable option for treating severely MIH affected teeth.</b>	
<b>Number of Patients evaluated: 44 patients Number of restorations: 60 restorations</b>	





## References – Clinical studies

### EQUIA<sup>®</sup> Forte

<b>TITLE</b>	Clinical performance of a glass-hybrid system compared with a resin composite in the posterior region: Results of a 2-year multicenter study
<b>REFERENCE</b>	Miletic <i>et al</i> , J Adhes Dent. 2020;22(3):235-247. doi: 10.3290/j.jad.a44547.
<b>In this split-mouth study design, EQUIA Forte performed as good as the nanohybrid resin composite (Tetric EvoCeram) in moderate to large two-surface class II restorations.</b>	
<b>Number of Patients evaluated: 180 patients</b> <b>Number of restorations: 360 restorations</b>	

<b>TITLE</b>	A Clinical Evaluation of Conservative approach and GIC Performance in MIH Affected Molars: Three-year Results
<b>REFERENCE</b>	Tugcu N, et al, iapdworld.org/congress-3/iapd20-virtual, abstract book p.1076
<b>EQUIA Forte combined with minimal invasive cavity preparation was found to be a successful approach during a 3-year follow-up.</b>	
<b>Number of Patients evaluated: 31 patients</b> <b>Number of restorations: 65 restorations</b>	